Literature DB >> 22762926

Colistin past and future: a bibliographic analysis.

Ernest A Azzopardi1, Elaine L Ferguson, David W Thomas.   

Abstract

OBJECTIVE: Colistin is a venerable drug that has found renewed interest because of multidrug resistance (MDR) and the shortfall of effective antibiotics. We present a synthesis of publication trends on MDR infection, colistin, and its adverse events, as a measure of the medical-academic community's interest, to inform current redevelopment strategies.
DESIGN: This was a multidatabase electronic search over 50 years with back- and forward-referencing through Web of Knowledge. Studies were grouped into MDR, colistin, and adverse events and were plotted in 5-year clusters.
RESULTS: Three periods could be mapped with distinct literature trends: A, 1940 to 1975; B, 1975 to 2000; and C, post-2000. Period A was characterized by increasing publications, soon followed by adverse-effect-themed publications. Period B reported a sharp publication decline; and period C reported a sharp increase in interest, mirroring the exponential increase in MDR literature. Period B predated standardized modern pharmacologic requirements. Period C coincided with novel drug development techniques. DISCUSSION: Two current trends (period C) were identified. Optimization of the current formulation may have been influenced by period B. Current research efforts within this trend include pharmacokinetic/pharmacodynamic analysis, purification, formulation, and resistance surveillance. The second trend involved colistin's redevelopment by tailored chemical reengineering to produce novel and patentable chemical entities, with an interdisciplinary approach emphasis. It is hoped that an analysis of the interplay between historical trends and current redevelopment strategies of this colistin case study may highlight strategies to stoke the drying antibiotic pipeline. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22762926     DOI: 10.1016/j.jcrc.2012.04.008

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  7 in total

1.  Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model.

Authors:  Stéphane Corvec; Ulrika Furustrand Tafin; Bertrand Betrisey; Olivier Borens; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

2.  Polymyxin B containing polyion complex (PIC) nanoparticles: Improving the antimicrobial activity by tailoring the degree of polymerisation of the inert component.

Authors:  Ignacio Insua; Laimdota Zizmare; Anna F A Peacock; Anne Marie Krachler; Francisco Fernandez-Trillo
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

3.  Preparation and antimicrobial evaluation of polyion complex (PIC) nanoparticles loaded with polymyxin B.

Authors:  Ignacio Insua; Sieta Majok; Anna F A Peacock; Anne Marie Krachler; Francisco Fernandez-Trillo
Journal:  Eur Polym J       Date:  2017-02       Impact factor: 4.598

4.  Serum Cystatin C for Evaluation of Acute Kidney Injury in Adults Treated with Colistin.

Authors:  Rozina Abbasi Larki; Bahareh Jamali; Mohsen Meidani; Sarah Mousavi
Journal:  J Res Pharm Pract       Date:  2018 Oct-Dec

5.  Polymyxin E Induces Rapid Paenibacillus polymyxa Death by Damaging Cell Membrane while Ca2+ Can Protect Cells from Damage.

Authors:  Zhiliang Yu; Yuanning Cai; Wangrong Qin; Jianxun Lin; Juanping Qiu
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

6.  Enzyme-responsive polyion complex (PIC) nanoparticles for the targeted delivery of antimicrobial polymers.

Authors:  Ignacio Insua; Evangelos Liamas; Zhenyu Zhang; Anna F A Peacock; Anne Marie Krachler; Francisco Fernandez-Trillo
Journal:  Polym Chem       Date:  2016-03-24       Impact factor: 5.582

7.  Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection.

Authors:  Zhijin Chen; Yu Chen; Yaogao Fang; Xiaotian Wang; Yanqing Chen; Qingsong Qi; Fang Huang; Xungang Xiao
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.